2022 vol 1 issue 1
Full paper
Urszula A. Szymańska(1)*, Marcin Kurzyna(2), Agnieszka Segiet-Święcicka(3), Piotr Kułak(1), Dariusz A. Kosior(1,4)
(1) Department of Cardiology and Hypertension, Central Research Hospital, Ministry of the Interior and Administration, Warsaw (Poland)
(2) Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Centre of Postgraduate Education, European Health Centre Otwock, Otwock (Poland)
(3) Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw (Poland)
(4) Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, (Poland)
Correspondence to: urszula.szymanska@cskmswia.gov.pl
Pages 36-45
DOI: 10.58332/v22i1a03
Abstract
Acute pulmonary embolism (APE) is one of the main causes of cardiovascular deaths and anticoagulant treatment plays a key role in preventing recurrent episodes, chronic thromboembolic pulmonary hypertension (CTEPH), and deaths. The aim of this study is to assess the real-life trends and to determine factors associated with the choice of anticoagulation therapy in patients with APE. This is a single center prospective open study. We followed 178 consecutive patients admitted to the tertiary clinical center with APE proven with computed tomography (CT) scan within period of 24 months. A total number of 178 patients with APE were enrolled in the study. 48.9% of subjects were hospitalized in cardiology department. As a prolonged anticoagulant therapy 35.7% of study cohort received direct oral anticoagulants (DOACs), 35.1% LMWH, and 29.2% vitamin K antagonists (VKA), respectively. No statistically significant differences were found between the departments regarding frequency of prescribing anticoagulants (p=0.15). The multivariable analysis showed that oral anti-coagulants (OACs) were less likely to be prescribed than LMWH in patients with malignancy, history of major bleeding, serious medical condition and altered mental status. OACs were preferred over LMWH in symptoms of deep vein thrombosis (DVT). VKA were significantly less likely to be chosen than DOACs in patients with history of orthopaedics procedure. After six months anticoagulation therapy was discontinued in 24.3% of patients. Concluding, the form of anticoagulant therapy was associated with the presence of chronic diseases. LMWH was prescribed in high bleeding risk patients more frequently.
Keywords
anticoagulation, low molecular weight heparin, direct oral anti-coagulants, pulmonary embolism, vitamin K antagonists
First published: 18.11.2022